Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

Press Published by 3rd Party PR Representative on:  
Drew Sturtevant, Ph.D.
Sr. Associate, Scientific Affairs and Communications

Please find more information at:
Lantern Pharma’s Website:
Lantern Pharma’s Monthly Newsletter – SPARK: Sign-up here
Twitter: @lanternpharma